30 closest matches · ranked by relevance
Cyclic Vomiting Syndrome
Primary: The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period. — 0.69; 1.43; 1.33; 1.48 event — p=0.7024
Cyclic Vomiting Syndrome · Abdominal Migraine
Primary: Rhodes Index of Nausea, Vomiting & Retching (INVR) — 3.25; 5.80; 10.43; 0.75 score on a scale
Cyclical Vomiting
Primary: Nausea Visual Analog Scale — 41; 61 mm
Cyclic Vomiting Syndrome
Primary: State-Trait-Anxiety Inventory (STAI) (18) and Profile of Mood States (POMS) — 34.59; 35.05; 26.27; 41.67 score on a scale
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
Vestibular Migraine
Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale
Gastroparesis
Primary: Number of Participants With Improvement in Nausea — 29; 25 participants — p=0.43
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Congenital Sucrase-isomaltase Deficiency (CSID)
Primary: Prevalence of CSID Genetic Variants — 27; 0 Participants
Syncope, Vasovagal
Primary: Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test — 32; 27; 33; 35 Participants — p=0.521
Post COVID Syndrome · Fatigue · Headache
Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Abdominal Pain · Anxiety
Primary: Clinical Global Impression Scale - Improvement (CGI-I) Will be Used to Assess Overall Global Illness Improvement. CGI-I Scores of 1 (Very Much Improved) or 2 (Much…
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Hyperemesis Gravidarum · Pregnancy Related
Primary: Blood Cholecystokinin (CCK) Levels — 53.13; 54.55; 73.61; 81.24 picogram/mililiters (pg/ml) — p=0.05
Gastroenteritis · Gastritis
Primary: Treatment Success From 30 Minutes Through 24 Hours After First Dose of Study Medication - ITT Population — 126; 70; 12; 5 Participants — p=0.0406
Chemotherapy-Induced Nausea and Vomiting
Primary: Number of Patients Who Reported No Vomiting — 324; 252 Participants — p=<0.01
Familial Dysautonomia
Primary: Composite Daily Score — 6.9; 9.7 units on a scale
Gastroparesis · Dyspepsia
Primary: Gastric Emptying Half-time (T1/2) of Solids — 128.7; 125.8; 246.4; 198.4 minutes
Chest Pain
Primary: Frequency of Chest Pain Episodes — 1; 3 participants
Chronic Idiopathic Constipation
Primary: Overall Responder 9/12 Weeks — 18.6; 16.8; 19.0; 10.7 % of Overall Responder 9/12 weeks
Cluster Headache
Primary: Number of Participants With Repsonse to Treatment — 14; 16; 57; 44 Participants
Gastroparesis
Primary: GCSI-DD Total Composite Symptom Scores. — 1.89; 1.57; 1.34 score on a scale — p=<0.01
Postoperative Nausea and Vomiting
Primary: Number of Patients With Nausea, Emesis, Severe Nausea, Severe Emesis and Number Receiving Rescue Antiemetics in the Post-Anesthetic Care Unit (PACU) — 60; 13; 8; 2…
Chronic Intestinal Pseudo-obstruction
Primary: Mean Change in Weekly Global Gastrointestinal Symptoms Average Index Score (WGGSAIS). — -0.424; -0.185 score — p==0.1279
Irritable Bowel Syndrome
Primary: Colonic Transit Geometric Center at 24 Hours — 3.12; 3.05; 2.77 units on a scale
Gastroparesis
Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69
Colorectal Cancer · Nausea · Vomiting
Primary: Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy — 64; 34; 100 percentage of participants — p=.05